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ABSTRACT
DNA-PKcs and Ku are essential components of the
complex that catalyzes non-homologous end joining
(NHEJ) of DNA double-strand breaks (DSBs). Ku, a
heterodimeric protein, binds to DNA ends and facil-
itatesrecruitmentofthecatalyticsubunit,DNA-PKcs.
WehaveinvestigatedtheeffectofDNAstrandorienta-
tion and sequence bias on the activation of DNA-PK.
In addition, we assessed the effect of the position
and strand orientation of cisplatin adducts on kinase
activation. A series of duplex DNA substrates with
site-specific cisplatin–DNA adducts placed in three
different orientations on the duplex DNA were pre-
pared. Terminal biotin modification and streptavidin
(SA)blockingwasemployedtodirectDNA-PKbinding
to the unblocked termini with a specific DNA strand
orientation and cisplatin–DNA adduct position. DNA-
PK kinase activity was measured and the results
reveal that DNA strand orientation and sequence
bias dramatically influence kinase activation, only a
portion of which could be attributed to Ku-DNA
binding activity. In addition, cisplatin–DNA adduct
position resulted in differing degrees of inhibition
depending on distance from the terminus as well
as strand orientation. These results highlight the




DNA double-strand breaks (DSBs) are one of the most lethal
types of DNA damage, and eukaryotic cells have evolved two
major pathways to repair DSBs, homologous recombination
(HR) and non-homologous end joining (NHEJ). The NHEJ
pathway requires the heterodimeric protein Ku, which consists
of a 70 kDa subunit and 80 kDa subunit (1). Ku binds to the
ends of DSBs and recruits the 470 kDa DNA-PK catalytic
subunit (DNA-PKcs). Together Ku and DNA-PKcs make
up the complex termed DNA-PK holoenzyme. DNA-PK
activation, an essential step in the repair process, occurs
once the kinase assembles at the site of DSB. The activation
of DNA-PK may signal to other downstream components
involved in signal transduction of the damage event (2).
This active DNA-PK complex may then recruit other factors
including the MRN complex (3), Artemis (4) and the DNA
ligase IV/XRCC4 complex (5), which are potentially involved
in processing of the termini and completing the repair process.
The interaction of Ku with DNA has been the subject of
extensive analysis. DNA double-stranded termini display the
greatest afﬁnity for Ku (6). A signiﬁcant advance in our
understanding of Ku structure and function was revealed when
the co-crystal structure of Ku bound to a duplex DNA was
determined (7). In this structure, each subunit of Ku encircles
the duplex DNA in a ring-like structure, with a large base on
which the DNA rests. Two pillars support a bridge-like struc-
ture through which the DNA strand can thread. Further ana-
lysis of this crystal structure reveals that while there are no
direct interactions with the DNA bases, speciﬁc amino acids
protrude into the major and minor grooves of the DNA so as to
provide a helical guide through the ring structure of Ku (7).
Additional studies have revealed that Ku binds and orients
itself at a DNA terminus in a very speciﬁc fashion. This was
highlighted in a series of photo-cross-linking experiments
where short duplex DNA substrates were used to demonstrate
that at a DNA terminus, Ku 80 is positioned more internally
and Ku 70 is positioned closer to the terminus (8,9). In addi-
tion, Ku 70 was observed to make speciﬁc contacts within the
major grooveintheDNAhelix,whileKu80doesnotappearto
contact the major groove but is oriented in proximity of the
minor groove (9). These results indicate that while Ku binding
is not sequence speciﬁc, alterations in duplex structure could
inﬂuence the DNA binding activity of Ku.
After Ku binds to a double-stranded DNA terminus, it
recruits DNA-PKcs to the site of the break. Electron crystal-
lography at 22 s resolution revealed an open channel in the
DNA-PKcs structure that could interact with double-stranded
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doi:10.1093/nar/gki157DNA (10). Studies show that on short DNA substrates, the
association of DNA-PKcs causes Ku to move further along the
length of the duplex DNA (8). DNA-PKcs was demonstrated
to make direct contact with approximately the ﬁrst 10 bp along
a duplex DNA substrate (8). Electron micrographic studies
also show that dramatic conformational changes accompany
DNA-PKcs binding to DNA (11). These conformational
changes were postulated to be involved in activation of the
kinase, which in turn could facilitate recruitment of other
proteins involved in the repair process (11). Considering that
DNA-PKcs is maximally activated by double-stranded DNA
containing un-annealed single-strand segments (10), how
these substrates inﬂuence the DNA-PKcs conformational
changes is of signiﬁcant interest.
While much is known about the repair of single sites of
DNA damage or strand breaks, considerably less is known
concerning the repair of compound lesions on DNA. One
study has assessed the effect of terminal nucleotide modiﬁca-
tion on the activation of DNA-PK. The results demonstrate
that DNA-PK is largely unaffected by terminal base modiﬁca-
tion (12). The presence of a cisplatin adduct in the vicinity of a
DNA DSB represents a compound lesion potentially encoun-
tered by NHEJ proteins in cells treated with concurrent cis-
platin and IR. Cisplatin is a DNA damaging agent that forms
DNA adducts preferentially at adjacent guanine bases in
duplex DNA (13). The effect of cisplatin lesions on Ku bind-
ing and DNA-PKcs activation has been studied, and results
show that Ku has a similar binding afﬁnity for cisplatin-
damaged DNA as compared to a control DNA of identical
sequence without the cisplatin adducts (14). Cisplatin adducts
on duplex DNA strands were also demonstrated to decrease
Ku’s ability to translocate along the DNA, away from the
terminus to which it was originally bound (15). Interestingly,
despite Ku and DNA-PKcs binding, activation of DNA-PKcs
kinase activity was signiﬁcantly reduced on cisplatin-damaged
DNA (14,15). To further investigate the effect of compound
lesions and the speciﬁcity of the DNA on the DNA/DNA-PK
interaction, we prepared a series of modiﬁed DNA duplex
substrates focusing on sequence bias and strand orientation.
These results are discussed with respect to Ku and DNA-PK
structure and function, and NHEJ-catalyzed repair of DNA
DSBs.
MATERIALS AND METHODS
Preparation of DNA substrates
The 30mer single-strand oligonucleotides used in this study
are presented in Table 1. Oligonucleotides were purchased
from Integrated DNA Technology (Coralville, IA), gel puri-
ﬁedbypreparativedenaturing polyacrylamidegelelectrophor-
esis, and treated with cisplatin as described previously (14),
with the followingmodiﬁcation.Thecisplatin waspre-aquated
by incubationwith AgNO3(16) andthe ratio ofcisplatin toGG
site was 10:1 for all cisplatin modiﬁcation reactions. The
degree of cisplatin modiﬁcation was assessed by analytical
DNA sequencing gel analysis or exonuclease digestion, and
in some cases the platinated DNA strands were puriﬁed by
preparative gel electrophoresis, to assure that 100% of the
DNA substrates were platinated. The control and platinated
DNA strands were eluted from the gel, ethanol precipitated,
quantiﬁed and annealed to the appropriate complement to
generate the duplex DNA substrates depicted in Figure 1.
Duplex DNA substrates were puriﬁed by native polyacryla-
mide gel electrophoresis, eluted from the gel, precipitated and
quantiﬁed.
Additional oligonucleotides were designed to generate
DNA substrates containing homopolymeric termini. A 15 base
50 biotinylated oligonucleotide was designed to be annealed to
complementary 15 base oligonucleotides that have various
homopolymeric 50 extensions. Subsequent extension of the
50 biotinylated primer results in the formation of a
duplex DNA with one terminus capable of being blocked
by streptavidin (SA) and the other terminus having a deﬁned
homopolymeric 30 and 50 accessible terminus. Extension of the
biotinylated strand was performed with 100 mM dNTPs and
Table 1. DNA oligonucleotides
DNA Sequence
a Function
3P 50-CCTCTCTCCTTCTTTTCCTCTTCGGTCTCC-30 Platinum adduct at 30 terminus
5P 50-CCCCTGGCTTTCTTTTCCTCTTCCTTCCCC-30 Platinum adduct at 50 terminus
MP 50-CCCCTCTCCTTCTTGGCTTCTTCCTTCCCC-30 Platinum adduct central
3Pc3B 50-GGAGACCGAAGAGGAAAAGAAGGAGAGAGGbiotin-30 Complement to 3P
5Pc5B 50-biotinGGGGAAGGAAGAGGAAAAGAAAGCCAGGGG-30 Complement to 5P
MPc3B 50-GGGGAAGGAAGAAGCCAAGAAGGAGAGGGGbiotin-30 Complement to MP












2.1 50-CCCCTATCCTTTCCGCGTCCTTACTTCCCC-30 EMSA substrate
2.2 50-GGGGAAGTAAGGACGCGGAAAGGATAGGGG-30 Complement to 2.1
aThe position of the cisplatin modification is indicated by the underlined base.
Nucleic Acids Research, 2005, Vol. 33, No. 1 15310 U/reaction of Sequenase polymerase, incubated for 30 min
at 37 C, and the reaction stopped with 100 mM EDTA. The
duplexes generated from the extension were puriﬁed using a
G-50 mini-column and quantiﬁed. A similar procedure was
followed to generate the duplexes containing 15 bases of a
single nucleotide at both ends of a mixed 15 base sequence
(Figure 1A).
Protein purification
Human Ku was puriﬁed from recombinant baculovirus-
infected Sf-9 insect cells. Transfer vectors containing
N-terminal [His]6 tagged Ku 70 and full-length Ku 80 were
generously provided by Dr Dale Ramsden (University of
North Carolina). Sf-9 cells were co-infected with Ku 70 and
Ku 80 recombinant virus at a multiplicity of infection of 5
and 10, respectively. Cells were infected for 48 h, after which
cell-free extracts were prepared and Ku was puriﬁed via
sequential Ni-NTA agarose and Q-Sepharose column chroma-
tography, as previously published (5). Fractions containing Ku
were identiﬁed using SDS–PAGE and Coomassie staining,
and peak fractions were pooled, dialyzed and stored at
 80 C until use.
DNA-PKcs was puriﬁed from cell-free extracts prepared
from 16 l of HeLa cells. Extracts were prepared as previously
described (17), and fractionated on a 50 ml cisplatin-damaged
DNA–Sepharose column and phosphocellulose column, as
previously described (14). Further puriﬁcation and separation
of the DNA-PK catalytic subunit from Ku subunits was
achieved by chromatography on a 5 ml hydroxylapatite col-
umn. Protein (0.3 mg) was loaded on a 5 ml column and
washed with buffer containing 10 mM KPi. Proteins were
eluted with a 50 ml linear gradient from 10 to 500 mM
KPi. DNA-PKcs containing fractions were identiﬁed by
Coomassie staining of SDS gels and Ku-DNA dependent
protein kinase activity, as previously described (14).
Active fractions were pooled, dialyzed and stored at  80 C
until use.
DNA-PK kinase assays
Assays were performed at 37 C in a ﬁnal volume of 20 ml
containing 20 mM HEPES, pH 7.5, 8 mM MgCl2, 1 mM DTT,
5% glycerol, [g-
32P]ATP (0.5 mCi, 125 mM), 2.1 nM DNA-
PKcs, 3.3 nM Ku, 5 nM DNA and 500 mM p53 synthetic
peptide. In reactions using SA–DNA complexes, the DNA
was mixed with 1 ng SA/fmol DNA and incubated on ice
for 5 min. Ku and DNA-PKcs were added to reaction buffer
containing the peptide and incubated on ice for 5 min. The
DNA substrate was then added and incubation continued for
an additional 5min on ice. Reactions were then initiated by the
addition of ATP and incubated for 15 min at 37 C. Reactions
were terminated by the addition of an equal volume of 30%
acetic acid and were spotted onto P81 phosphocellulose ﬁlter
paper. The ﬁlters were washed ﬁve times for 5 min each in
15% acetic acid, once in 100% methanol, and allowed to dry.
Samples were quantiﬁed by PhosphorImager analysis using
ImageQuant software (Molecular Dynamics).
Competition binding analyses
Electrophoretic mobility shift assays (EMSAs) were per-
formed in 20 ml reactions containing 50 mM Tris–HCl,
10 mM MgCl2 and 50 mM NaCl. In reactions containing
SA–DNA complexes, SA was pre-incubated with competitor
DNA substrates (1 ng SA/fmol DNA) for 5 min. Increasing
amounts of the unlabeled competitor SA–DNA complex
were then mixed with 2.5 nM
32P-labeled double-stranded
2.1/2.2 DNA (18), followed by 5 nM Ku. Reactions without
SA were carried out in the same manner, except that
the competitor DNA was added to the labeled DNA
Figure 1. DNA substrates used in this study. (A) Duplex DNA substrates were
prepared from the single-stranded oligonucleotides presented in Table 1 as
described in Materials and Methods. The addition of SA, as indicated by the
oval,resultsin blockingofthe biotinylatedterminus,indicatedby the redletter
‘B’. The cisplatin adducts are positioned either 6 or 15 bp from the accessible
terminus in the 5P and 3P series, and MP series of substrates, respectively. The
substrates generated have either a 50 pyrimidine-rich strand (5P series) or a
30 pyrimidine-rich strand (3P series) accessible to Ku when SA blocking is
employed. The remaining substrates represent duplexes that were designed to
containamixed15basesequence,indicatedbytheblackjaggedline,andeither
15 bases of dAs or dTs on the 30 strand, 45 bases of dAs or dTs with two dCs or
dGsplaced6bpin,orsubstrateswiththe15basemixedsequencecontaining15
bases of dTs or dAs on both sides. (B) Ku and DNA-PKcs were purified as
described in Materials and Methods: 200 ng of DNA-PKcs and 400 ng of Ku
were separated on an 8% SDS–PAGE gel and silver stained. The position and
molecularweights(kDa)ofthestandardsareindicatedontheleft-handside.(C)
In the presence of SA, the 3P/3B substrate and the same substrate with an
additional biotin modification on the remaining 30 end were assayed for
DNA-PK kinase activation as described in Materials and Methods. Reactions
contained 20 nM DNA-PKcs, 3.3 nM Ku and 5 nM SA–DNA, as indicated.
Resultsarepresentedasthepmolof
32Ptransferredtothesyntheticp53peptide
in a 30 min reaction. Reactions were performed in triplicate and the mean and
standard error of the mean are presented.
154 Nucleic Acids Research, 2005, Vol. 33, No. 1directly. Reactions were mixed and loaded onto a 6%
native polyacrylamide gel. Gels were dried and exposed to a
PhosphorImager and quantiﬁed using ImageQuant software.
RESULTS
DNA substrates to assess the effect of DNA strand
polarity, sequence bias and platinum adduct
position on DNA-PK activation
Ku, a major player in the DNA DSB repair process, arrives at
the site of a break and binds to the terminus created by the
break. This facilitates the recruitment of DNA-PKcs, which in
turn initiates the repair process. While it is known that Ku has
a high binding afﬁnity for double-stranded DNA, the effect of
different duplex structures or sequences on Ku binding and
DNA-PKcs activation have not been determined. To assess the
relative binding afﬁnity of Ku for different DNA substrates
and the subsequent activation of DNA-PK, substrates were
designed that would limit binding of the protein complex to
the speciﬁc DNA terminus in question. Biotin modiﬁcation
with SA blocking of the speciﬁc ends of the substrates was
employed to create the desired substrates (Figure 1A). When
SA was bound to the biotin-modiﬁed ends of the 30mer sub-
strates, that end of the DNA duplex was sufﬁciently blocked
so that Ku and DNA-PKcs could not bind. This results in the
accessible terminus containing 30 pyrimidine- and 50 purine-
rich strands and 30 purine- and 50 pyrimidine-rich strands
(Figure 1A). Individual substrates 3P/3B, 5P/5B, MP/3B
and MP/5B were designed to also allow the incorporation
of site-speciﬁc cisplatin adducts at two positions, 6 bp or
15 bp from the accessible terminus. These sites were posi-
tioned on the 30 pyrimidine (3P/3B and MP/3B) or 50 pyrimi-
dine (5P/5B and MP/5B) rich strands to allow the effect of
strand polarityon adduct position to bedetermined. Additional
oligonucleotides consisting of a mixed complement sequence
with an additional either 50-T15 or 50-A15 were synthesized and
annealed to the biotin-modiﬁed oligonucleotide. The modiﬁed
oligonucleotide was then extended by polymerase-catalyzed
extension to create a blunt-ended, fully duplex DNA substrate,
and after blocking with SA, the resulting substrate contains
either a 30-T15 50-A15 termini (30-T, Figure 1A) or a 30-A15 
50-T15 termini. To assess the inﬂuence of purine bases within
the homopolymeric pyrimidine sequence, an oligonucleotide
was designed to contain a 50-A5G2A23, such that when
annealed and extended, two guanines were positioned six
bases from the 30 termini of a pyrimidine-rich sequence
(30-T/GG, Figure 1A). The corresponding 30-A/CC was also
prepared using a similar methodology. Biotin modiﬁcation
was eliminated completely on another set of substrates
(30-T/30-T, Figure 1A) that had a 15 base mixed sequence
ﬂanked by 30 dTs or dAs. Using this combination of substrates,
differences in DNA strand polarity, sequence bias and position
of the cisplatin adduct on DNA-PKcs kinase activation and Ku
binding could be determined.
Ku and DNA-PKcs were puriﬁed separately and the DNA-
PK holoenzyme was reconstituted to enable the analysis of
DNA-PK activation by the different DNA substrates. This
approach also allowed the determination of Ku binding to
the DNA substrates, independent of DNA-PKcs. Human Ku
was prepared from insect cells infected with recombinant
baculovirus (5). DNA-PKcs was puriﬁed from HeLa cell
extracts (14,19). The ﬁnal pools of protein were subjected
to analysis by SDS–PAGE and stained with silver (Figure
1B). As expected, the Ku subunits migrated consistent with
molecular masses of 70 and 80 kDa, and DNA-PKcs migrated
slower than the 200 kDa marker and is consistent with the
predicted molecular mass of 460 kDa. The DNA PKcs pre-
paration does contain a low level of Ku judged to be <5%
of the DNA-PKcs. This was conﬁrmed in kinase assays where
the activity of DNA-PKcs was signiﬁcantly stimulated by the
addition of the recombinant Ku (data not shown). A series of
preliminary experiments were performed to determine the op-
timal concentrations for the kinase assays of Ku, DNA-PKcs
and DNA for in vitro kinase activation (data not shown). In
other experiments, increasing concentrations of SA were
titrated with the biotinylated DNA to determine the minimal
amount necessary to quantitatively bind the DNA substrate
(data not shown). The efﬁciency of SA binding and blocking
of the biotinylated terminus was assessed on a substrate
prepared with both termini bound by SA (Figure 1C). The
results demonstrate that with both ends bound by SA, an
80% decrease in activity was observed compared to a substrate
with one terminus bound by SA.
Effect of cisplatin–DNA adduct position and
DNA strand polarity on activation of DNA-PK
We have previously shown that Ku is able to bind to cisplatin-
damaged double-stranded DNA with a similar afﬁnity as to
undamaged duplex DNA, but that cisplatin-damaged DNA is a
less effective activator of DNA-PK (19). To date,however, the
effect of cisplatin adduct position in relation to strand polarity
has not been determined. Using the substrates presented in
Figure 1A, we have determined that adduct position inﬂuences
DNA-PK kinase activation. The DNA-PK kinase activity sup-
ported by the 3P/3B and 5P/5B substrates was assessed in
reactions performed with SA (Figure 2A). SA–biotin blocking
of the 3P/3B results in a 30 pyrimidine-rich accessible ter-
minus, and SA–biotin blocking of the 5P/5B substrate gener-
ates a 50 pyrimidine-rich accessible terminus. These results
demonstrate that the activity of DNA-PK was reduced to
near background levels when either the SA-3P/3B and SA-
5P/5B substrates were modiﬁed with cisplatin such that the
cisplatin–DNA adduct was 6 bp from termini (Figure 2A,
closed bars). Therefore, inhibition of DNA-PKcs activity by
cisplatin is not inﬂuenced by the strand, 50 or 30, on which the
cisplatin–DNA adduct resides. These data suggests that cis-
platin-dependent inhibition of DNA-PK is a function of the
structural alteration in the duplex induced by the cisplatin–
DNA adduct.
Interestingly, in control reactions performed using DNA
substrates prepared without cisplatin, a signiﬁcant difference
in the degree of kinase activation was observed with the two
different substrates (Figure 2A, open bars). Kinase assays
performed using the 5P/5B substrate resulted in signiﬁcantly
lower DNA-PK activity compared to that obtained with the
3P/3B substrate. The only major difference between the 3P/3B
and 5P/5B substrates is the base composition in reference to
the DNA strand polarity of the accessible termini. Therefore,
these data are consistent with DNA-PK being differentially
activated dependent on sequence bias and strand polarity, with
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In a series of control experiments, we assessed the activa-
tion of DNA-PK by each substrate without the use of SA
(Figure 2B). The results obtained are consistent with either
the 30 biotin modiﬁcation or 30 purine-rich terminus resulting
in signiﬁcantly less DNA-PK activity. The 30 biotin modiﬁca-
tion inhibition was ruled out, as biotin modiﬁcation of both
30 termini resulted in kinase activation at levels similar to
reactions using substrates of identical sequence without the
biotin modiﬁcation (data not shown).
Ku binding
To determine if differential kinase activity was attributable to
the afﬁnity of Ku for the DNA substrates, a series of competi-
tion DNA binding assays were performed. For competition
assays, Ku was added to reactions containing a
32P-labeled
duplex DNA and increasing concentrations of the unlabeled
competitor DNA (3P/3B, 5P/5B). These assays allowed for the
indirect determination of the relative afﬁnity of Ku for the
different DNA substrates without having to
32P-label each
DNA to be tested. The results of a typical competition
assay are presented in Figure 3A and B. Increasing concentra-
tions of SA-3P/3B DNA (lanes 3–5) were titrated into reac-
tions containing ﬁxed concentrations of Ku and
32P-labeled
duplex DNA, and the results show a decrease in the level of
Ku bound to
32P-labeled DNA. This decrease in Ku binding to
the labeled DNA corresponds to the increased amount of
Ku bound to the competitor DNA. The analysis of the identical
sequence, with the addition of the site-speciﬁc cisplatin lesion
(SA-3P/3B + Pt), is presented in lanes 6–8. Again, a decrease
in Ku bound to
32P-labeled DNA was observed, although it
was not as dramatic as the decrease observed for 3P/3B   Pt.
Quantiﬁcation of the results by PhosphorImager analysis
revealed a 2-fold difference in Ku binding to the labeled
DNA in the presence of the highest concentration of compet-
itor DNA. In the presence of the undamaged competitor DNA,
Ku binding was 10% of the control value observed in the
absence of competitor (compare Figure 3A, lanes 2 and 5).
In the presence of cisplatin-damaged competitor, the level of
Ku binding the labeled substrate was 20% of control (lanes 2
and 8). This 2-fold difference in binding the labeled DNA
calculates to a 10% difference in Ku afﬁnity for the competitor
DNAs. Similar quantiﬁcation of the intermediate concentra-
tion of competitor was performed and the difference was sim-
ilar, at  22%. These results indicate that the cisplatin adduct
on the substrate only partially hinders Ku’s ability to bind. The
same effect of cisplatin is observed in reactions comparing Ku
Figure 3. Effectofstrandbias,sequencespecificityandcisplatin–DNAadduct
position on Ku binding. (A) Competition binding assays were performed in
20mlreactionsandcontained2.5nM
32P-labeleddouble-stranded2.1/2.2DNA
and 5 nM Ku. Increasing concentrations of the SA-bound competitor DNA
(3P/3B), 5, 50 and 200 nM is indicated by the triangles. Controls for the
assay include
32P-labeled double-stranded 2.1/2.2 DNA alone (lane 1) and
32P-labeled double-stranded 2.1/2.2 DNA with 5 nM Ku in the absence of
any competitor (lane 2). (B) Competition assays were carried out identically
to those in (A) except reactions included 5P/5B competitor DNA.
Figure 2. Effectofstrandbias,sequencespecificityandcisplatin–DNAadduct
position on kinase activation. (A) The cisplatin-damaged or control double-
stranded SA-3P/3B and SA-5P/5B 30mers were assayed for DNA-PK kinase
activation as described in Materials and Methods. Reactions contained 20 nM
DNA-PKcs,3.3nMKuand5nMSA–DNA,asindicated.Resultsarepresented
as the pmol of
32P transferred to the synthetic p53 peptide in a 30 min reaction.
Reactions were performed in triplicate and the mean and standard error of the
mean are presented. (B) The cisplatin damaged or control double-stranded 3P/
3Band5P/5B30merswereassayedforDNA-PKkinaseactivationasdescribed
above, except SA was not included in the reaction. Results are presented as the
pmol of
32P transferred to the synthetic p53 peptide in a 30 min reaction.
Reactions were performed in triplicate and the mean and standard error of
the mean are presented.
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Again, only slightly less binding was observed with the
cisplatin-damaged DNA compared to the undamaged control
DNA (lanes 5 and 8). Quantiﬁcation of these data revealed the
differences in binding were <5% and not signiﬁcant. There-
fore, the dramatic decrease in kinase activation observed on
cisplatin-damaged DNA substrates (Figure 2A) is not accom-
panied by a dramatic decrease in Ku binding. This is apparent
in the comparison of Ku binding activity with the cisplatin-
damaged and control undamaged DNA substrates, where only
a slight decrease in Ku binding is observed, while DNA-PK
kinase activity is decreased by  95%.
The relative afﬁnity of Ku for the 30 pyrimidine-rich DNA
(3P/3B) versus 30 purine-rich DNA (5P/5B) can also be deter-
mined from these binding data. Comparison of the results
obtained with the undamaged control DNA substrates (Figure
3A and B, lanes 3–5) suggests that Ku has a slightly higher
afﬁnity for the 3P/3B substrate. When comparing the results
obtained in the Ku binding assays to kinase activation with
identical substrates, it is clear that differences in kinase
activation cannot be attributed to differences in Ku binding.
This conclusion is supported by a series of experiments where
increasing concentrations of DNA were titrated into kinase
reactions verifying that saturating DNA concentrations were
employed (data not shown).
Distance of cisplatin from terminus differentially
activates DNA-PK
Previous work from our laboratory has demonstrated that the
distance of the cisplatin adduct from the terminus to which
Ku and DNA-PKcs bind inﬂuences kinase activation (15).
Considering the dramatic reduction in kinase activity on the
cisplatin-damaged substrates with the cisplatin adduct
positioned 6 bp from the terminus, it was difﬁcult to assess
the signiﬁcance of cisplatin adduct position in terms of strand
polarity. Therefore, substrates were modeled after the 3P/3B
and 5P/5B substrates, with the cisplatin adduct moved to 15 bp
from the terminus (MP/3B and MP/5B). In reactions
performed with SA, cisplatin modiﬁcation resultsin a decrease
in kinase activity compared to undamaged control DNA
substrates on the 3P/3B series of substrates (Figure 2A). The
degree of cisplatin-dependent inhibition of kinase activity in
the presence of SA observed with the MP series of substrates
(Figure 4A) compared to that observed on the 3P series of
substrates (Figure 2A) is signiﬁcantly less, 60% compared to
the 95% inhibition. These results are consistent with previous
results from our lab which demonstrated that positioning a
cisplatin-modiﬁcation further from a terminus reduces the
degree of inhibition (15). Analysis of substrates with cispla-
tin-modiﬁcation of the 50 strand yielded negligible inhibition
when compared to control undamaged DNA. These data are
consistent with the interpretation that positioning the
cisplatin–DNA adduct further from the terminus limits
the degree of inhibition by the cisplatin lesion. Importantly,
the kinase activity supported by the MP/3B and MP/5B
cisplatin-damaged substrates was nearly equivalent, again
demonstrating that the strand polarity has a limited inﬂuence
on the degree of cisplatin inhibition of DNA-PKcs. Impor-
tantly, in the absence of cisplatin modiﬁcation, the 30 pyrimi-
dine-rich strand again was a more effective activator of the
kinase than the 50 pyrimidine-rich strand (Figure 4A, open
bars). These results conﬁrm the sequence bias and strand
polarity preference presented in Figure 2. In the absence of
SA and cisplatin, both MP/3B and MP/5B have an accessible
30 pyrimidine-rich end, resulting in similar activity levels with
the two different substrates (Figure 4B). In the presence of
cisplatin and the continued absence of SA, these substrates
result in a somewhat lower activity of DNA-PKcs, as expected
based on the position of the cisplatin adduct to the DNA
terminus.
The afﬁnity of Ku for the MP series of substrates was
also assessed in competition binding studies. The results
obtained with the cisplatin-damaged substrates are presented
in Figure 5. If the afﬁnity of Ku for a DNA substrate was
responsible for the differences observed in kinase activation,
we would expect Ku to display a higher afﬁnity for the MP/3B
substrate, as higher kinase activity was observed with this
substrate. Interestingly, the Ku binding analyses revealed a
somewhat higher afﬁnity for the MP/5B substrate compared
to the MP/3B substrate. This effect was observed for both
the unbound and SA-bound competitor DNA (Figure 5,
lanes 3–8 and 9–14). Quantiﬁcation of the results revealed
Figure 4. Effect of cisplatin–DNA adduct position, strand bias and sequence
specificity on kinase activation. (A) The cisplatin-damaged or control double-





reaction. Reactions were performed in triplicate and the mean and standard
error of the mean are presented.
Nucleic Acids Research, 2005, Vol. 33, No. 1 157a 10–20% difference in binding the competitor DNA (data not
shown). A similar result was also obtained in competition
analyses performed with the control series of undamaged
MP substrates (data not shown). Therefore, differences in
the activation of DNA-PK obtained with different DNA sub-
strates are not dictated by the afﬁnity of Ku for that speciﬁc
substrate.
DNA-PK is preferentially activated by 30 pyrimidine
and 50 purine strands
After having preliminarily established that DNA-PK is pref-
erentially activated based on strand bias and polarity, duplex
substrates were designed to allow a more rigorous determina-
tion of the sequence and polarity bias for DNA-PK activation.
Three 30mer substrates were designed to assess sequence bias
and polarity. The control substrate is a duplex 30 base mixed
sequence with equal base composition and a 50 biotin. The two
test substrates contain a biotinylated 15 base mixed sequence
followed by either 15 homopolymericdTs to generate a30 poly
T15 (30-T) or the substrate was prepared to contain a 30 poly dA
(30-A). Streptavidin blocking was employed to ensure that
speciﬁc ends of the duplex were made accessible for DNA-
PK binding, and kinase activity was assessed based on these
substrates. Results show that while DNA-PK is highly acti-
vated by the random sequence (Figure 6A, hatched bar),
it is also highly activated by a duplex that has a 30-T15 A15
(Figure 6A, closed bar). In contrast, a duplex made up of a
30-A15 T15 results in signiﬁcantly reduced DNA-PK activity
(Figure 6A, open bar). This data supports our previous data
that DNA-PK is preferentially activated by duplex ends
containing a 30 pyrimidine-rich strand and a 50 purine-rich
strand. A substrate prepared with a 15 base 30-G15 C15 gave
results similar to those observed with the 30-A terminus (data
not shown). Difﬁculty in chemical synthesis of a poly dG
template prohibited analysis of 30-C15 terminus.
The original substrates used when we ﬁrst discovered the
sequence bias in reference to kinase activation (3P/3B and
5P/5B) were designed to contain two purines in the pyrimi-
dine-rich strand (and subsequently two pyrimidines in the
purine-rich strand) in order to form cisplatin–DNA adducts.
After having established the preference of a 30 pyrimidine-rich
strand for the activation of DNA-PK, we were interested in
determining what effect these two nucleotides in a purine-rich
or pyrimidine-rich strand might have on activity of DNA-PK.
Therefore, a substrate was designed to contain two Gs in the
stretch of Ts on the 30 strand, and kinase activity was assayed
to determine if the two unfavored purines in the pyrimidine
strand would decrease activity. Results show that having two
purines (30-T/GG) positioned six bases from the terminus does
not adversely affect kinase activity otherwise observed with
this substrate (Figure 6B, closed bars). DNA-PK exhibits very
little activity with substrates designed with an accessible
30 purine-rich end and 50 pyrimidine-rich end. Interestingly,
the addition of two Cs within the homopolymeric 30-A results
in a nearly 2-fold increase in activity compared to the control
substrate containing only As (Figure 6B, open bars). This
signiﬁcantincreaseinactivityfurtherreinforcesthehypothesis
that DNA-PK is activated more by 30 pyrimidines than by
30 purines.
In order to ﬁnalize our ﬁndings that DNA-PK is preferen-
tially activated by 30 pyrimidine and 50 purine ends, we
designed a series of control substrates that eliminated the
necessity of biotin and SA. 30-T/30-T and 30-A/30-A have a
15 base stretch of 30 Ts or 30 As, respectively, on both sides of
the mixed sequence. We have shown that with a substrate that
has been blocked with SA and presents only one accessible
termini for DNA-PK binding that is made up of 30 purine and
50 pyrimidine strands, kinase activity is extremely low
(Figures 2, 4 and 6). We have also shown that when SA is
bound to biotin that is on opposite sides of a substrate (i.e. both
30 ends), activity is reduced to negligible amounts (Figure 1C).
Based on these ﬁndings, having 30 As on both ends of a duplex
substrate should be as ineffective in activating the kinase as a
SA-bound terminus is. The results in Figure 7 show that a
substrate with two 30-dA ends (Figure 7, open bars) causes
Figure 5. Effectofcisplatin–DNA adductposition onKu binding.Competition bindingassayswere performedin 20ml reactionsand contained2.5 nM
32P-labeled
double-stranded 2.1/2.2 DNA and 5 nM Ku. Increasing concentrations of the cisplatin-damaged competitor DNA 5, 50 and 200 nM, is indicated by the triangles.
The MP/3B and MP/5B substrates were pre-incubated with SA as indicated. Controls for the assay include
32P-labeled double-stranded 2.1/2.2 DNA alone (lane 1)
and
32P-labeled double-stranded 2.1/2.2 DNA with 5 nM Ku in the absence of any competitor (lane 2).
158 Nucleic Acids Research, 2005, Vol. 33, No. 1an 80% decrease in activity compared to a substrate with two
30-dT ends.
DISCUSSION
Ku and DNA-PKcs each have unique characteristics that con-
tribute to their afﬁnity for speciﬁc DNA substrates. The
co-crystal structure of Ku bound to a duplex DNA reveals
that the DNA is completely encircled by the Ku subunits,
while not making any speciﬁc base contacts (7). Therefore,
the speciﬁcity for different DNA substrates that we observe in
kinase activation is largely dictated by the DNA-PKcs and
how the DNA interacts with this subunit of the complex.
Our data suggest that the sequence or chemical make-up of
the speciﬁc DNA strands canmodulate the allosteric activation
of DNA-PK. Despite the structure-speciﬁc manner in which
Ku binds DNA, with the Ku 70 subunit being positioned closer
to the DNA end and the 80 subunit being positioned more
internally (9), the sequence bias, polarity and position of
cisplatin lesions have only a minimal effect on DNA binding.
Experiments show that DNA-PKcs possess a channel that
can accommodate double-stranded DNA, and upon binding
DNA, undergoes a fairly dramatic conformational change
that folds around the DNA, almost completely encircling
the duplex (11). It is possible that speciﬁc structures either
induce this change or accommodate the change better than
others. By using speciﬁc substrates with varying strand polar-
ity and sequence bias, as well as biotin and cisplatin modiﬁca-
tions, we have demonstrated that in reference to strand
polarity, different DNA substrates with speciﬁc sequences
can in fact result in differential activation of DNA-PK.
A model for DNA-PK activation and synapse activity in
NHEJ was proposed based on in vitro analysis of kinase
activation and electron microscopy of DNA–DNA-PKcs
complexes (20,21). Once DNA-PKcs has been recruited to
the ends of DNA with a DSB, it binds to the terminus of
both pieces of the broken DNA. The double-stranded DNA
protrudes through the kinase, and each frayed, single-stranded
DNA end deviates further from the other (10). The single-
stranded ends were then postulated to insert into potentially
two separate cavities or single-stranded DNA binding sites.
More recently, it has been shown that kinase activity is pref-
erentially activated by three bases of single-stranded dT ends
(12), but the preferred polarity of this nucleotide remains un-
deﬁned. Our data demonstrates that in terms of activating
DNA-PKcs, the cavities prefer a 30 pyrimidine-rich strand
and a 50 purine-rich strand (Figure 8A). A 30 purine-rich strand
and 50 pyrimidine-rich strand can reside in the cavities,
but results in reduced activity of DNA-PK (Figure 8B),
Figure 7. Effect of strand bias and sequence specificity in the absence of SA.
The 45mer substrates containing either 15 homopolymeric 30-dA on both sides
of a 15 base sequence of mixed base composition (30-A/30-A) or 30-dT on both
ends (30-T/30-T) were constructed by annealing T-5B-mixed with c-mixed-
15(T) or A-5B-mixed with c-mixed-15(A). Full duplex substrates were
generated by polymerase extension and each duplex was assayed for DNA-
PK activation at concentrations of 100 or 500 fmol of DNA as described in
Figure 2, except SA was not included.
Figure 6. Effect of homopolymeric sequences in regard to strand polarity on
kinase activiation. (A) 30mers containing 15 homopolymeric bases of 30-dT or
30-dAandacontrol30merofmixedsequencewereconstructedbyannealingthe
5B-mixedoligonucleotidetoeitherc-mixed-15(A),c-mixed-15(T)orc-mixed-
15, respectively. Full duplex substrates were generated by polymerase
extension and each duplex was assayed for DNA-PK activation as described
in Figure 2. (B) A control 45mer containing 30 homopolymeric bases of 30-dT
was compared to a 45mer containing 30 30-dT homopolymeric bases with two
dG six bases from the termini. These substrates were prepared by annealing
5B-mixed to a c-mixed-A or to c-mixed-A(CC), respectively, and extended. A
similar 45mer control substrate containing 30 homopolymeric bases of 30-dA
was compared to a 45mer containing 30 30-dA homopolymeric bases with two
dC six bases from the termini. These substrates were prepared by annealing
5B-mixed to a c-mixed-T or to c-mixed-T(GG), respectively, and extended.
Reactions were performed as described in Figure 2.
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kinase activation. Together, these results clearly demonstrate
that the discrimination for the single-stranded termini lies on
the 30 strand where a pyrimidine-rich sequence is preferred.
Our results, as well as those of Martensson et al. (12), are
inconsistent with the discrimination being dictated by the
50 strand. Our results are also consistent with in vitro analyses
measuring the ability of 30 and 50 single-strand DNA over-
hangs to activate DNA-PKcs in the absence of Ku, with a
preference being shown for 30 single-strand overhangs (20).
Considering the chemical structure of a pyrimidine is smaller
than that of a purine base, it will be interesting to determine the
degree to which chemical make-up and size of bases modulate
DNA-PK activity.
The experiments we conducted revealed several differences
in DNA that can result in an inactive DNA-PK complex.
Interestingly, the presence of a cisplatin–DNA adduct 6 bp
from the terminus of a substrate results in signiﬁcant inhibition
of DNA-PKcs kinase activity. The cisplatin–DNA adduct
results in a structural distortion in the DNA strand. Speciﬁc-
ally, cisplatin modiﬁcation of a duplex DNA results in a struc-
tural distortion of the strand, with a 78  bend in the DNA and a
25  untwisting of the structure (22). When the cisplatin adduct
is in close proximity to an accessible end of DNA, over 80%
inhibition of kinase activity compared to an undamaged
control is observed. The degree of inhibition caused by the
cisplatin adduct, however, is strand independent in that
cisplatin modiﬁcation of both the 30 or 50 strand resulted in
dramatic reduction in kinase activity. Although the speciﬁc
strand on which the cisplatin adduct resides does not affect
kinase activity, the position ofthe cisplatin adduct with respect
to the accessible terminus has a signiﬁcant inﬂuence on the
ability to activate DNA-PK. These results suggest that the
mechanism of inhibition may be a result of larger structural
differences in the duplex that inﬂuence either binding, con-
formational changes or correct positioning of the termini in the
30 cleft. We propose that a cisplatin adduct positioned 6 bp
from the terminus prevents the DNA from being fully threaded
through the kinase, thus not allowing the single-stranded ends
to wrap around and be placed in the activating cavities on
DNA-PKcs (Figure 8C). Assuming the cisplatin modiﬁcation
15 bp from the terminus also results in an inability to thread
through DNA-PKcs, there is still sufﬁcient DNA length from
the modiﬁcation to the end to result in the single-stranded
termini to gain access to the cavities (Figure 8D). This
model is consistent with other in vitro results demonstrating
the requirement of 18 bp duplex DNA for successful binding
of DNA-PKcs (11), and the ability of single-stranded DNA
tails to activate the kinase (10).
Analysis of our results indicates that the degree of DNA-PK
kinase activation is inﬂuenced by strand polarity, sequence
bias and position of a cisplatin adduct. These conclusions
can aid in forming a more detailed outline of how Ku and
DNA-PKcs play a role in NHEJ. For example, in NHEJ-
catalyzed repair of DNA double-strand breaks, DNA-PKcs
binds to each DNA terminus to be joined, and once activated
is thought to signal to other complexes involved in the repair
process. Electron microscopic and additional in vitro analyses
suggests that the DNA-PK complexes can be in close prox-
imity to each other and DNA-PKcs can serve to promote the
association of two DNA termini (21). Interestingly, this syn-
aptic activity has also been attributed to Ku independent of
DNA-PKcs (23). Independent of the mechanism, following
synapsis, alignment must occur with the correct polarity of
each broken strand, so that the 50 and 30 ends of the strands will
be ligated. The presence of damage, like that associated with
IR-induced DNA double-strand breaks, or having to search for
regions of microhomology, may necessitate processing of the
50 and 30 termini (24). Processing of the termini in NHEJ is
potentially catalyzed by two nuclease activities with opposing
directionalities. The MRN complex is capable of 30–50 exo-
nuclease activity and also contains an endonuclease activity
capable of digesting a 30 single-strand overhang (25,26). Arte-
mis contains an exonuclease activity capable of degrading
DNA in the 50–30 direction (27). The speciﬁc roles and sub-
strate speciﬁcity of the MRN complex and Artemis in proces-
sing DNA termini have not been conclusively demonstrated.
Our data, demonstrating the importance of the 30 strand of a
duplex DNA, and published data, demonstrating the prefer-
ence for a 30 single-strand to activate DNA-PKcs (20) suggests
that the 50–30 exonuclease activity of Artemis may be respons-
ible for generating a DNA structure capable of activating
DNA-PK. Our data demonstrate a clear preference for a
pyrimidine 30 terminus for DNA-PK activation. This data sug-
gests that either the 30–50 exonuclease activity of MRN or the
endonuclease activity of MRN could also generate a substrate
capable of activating DNA-PK and hence support NHEJ-
catalyzed repair of a DNA DSB. Clearly, further investigation
of how the chemical structure of the 30 ends of a substrate
Figure 8. Model for effect of strand polarity, sequence bias and platinum
position on the activation of DNA-PK. DNA-PKcs, denoted in gray, is
bound to different duplex substrates. The duplex DNA separates once it is
threaded through the kinase, and a single-strand can enter the 30 cleft,
depicted at the top of DNA-PKcs. The pyrimidine-rich strands of the
substrates are represented by a solid blue line and purine-rich strands
represented by a dotted green line. Cisplatin adducts are denoted by black
triangles on the duplex DNA, and are representative of the structural
distortions that the cisplatin–DNA adducts form in duplex DNA. The relative
kinase activity supported by each DNA substrate is indicated by the ‘+’
symbols.
160 Nucleic Acids Research, 2005, Vol. 33, No. 1inﬂuence the processing by MRN and Artemis, and activation
of DNA-PK, is of great interest.
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